Grand River buys more land to expand its manufacturing footprint in Michigan

Pills Getty
Fill-finish CMO Grand River Aseptic Manufacturing announced plans to expand its production capacity. (Getty)

Grand River Aseptic Manufacturing, a Michigan-based fill-finish CMO, said it has acquired a 1.5-acre plot of land near its current manufacturing facility as part of a planned expansion of its production capacity.

The lot, which is about a quarter mile from the company’s facility in Grand Rapids, Michigan, will eventually complement Grand River’s existing 40,000-square-foot space, the company said. When completed, the site will house a new cleanroom space, including new isolator technology, and will provide high-speed, fully integrated manufacturing and packaging lines.

Financial terms of the purchase, which is expected to close in 90 days, were not disclosed.

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

“The substantial growth rate that we’ve experienced in the last several years has allowed us to match the needs of our clients and the industry,” Tom Ross, Grand River’s president and chief executive, said in a statement. “With that growing demand, we are excited to add more manufacturing capacity, while remaining a quality-focused organization.”

In 2014, the company added a 28,000-square-foot addition to its pharmaceutical fill/finish facility.


Suggested Articles

The FDA is allowing some drugmakers to exceed the level of risk from a probable cancer-causing impurity in losartan for six months.

CDMOs Cambrex and Ajinomoto Bio-Pharma Services upgraded manufacturing plants, Takeda scored an albumin approval via its Shire deal, and more.

The FDA hit United Exchange Corp. with a warning letter, citing the company for a number of “significant” violations with its quality-control systems.